- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Clarivate Releases Top 100 Global Innovators 2022 List
Clarivate Plc has released the Top 100 Global Innovators™ 2022 list. Drawing on Clarivate™ data, the annual list identifies the organizations that demonstrate consistent, above-the-bar innovation excellence and which sit at the very top of the global innovation ecosystem.
As it relates to pharma and medtech, three companies in those industries have been identified in this year’s top 100 list, including:
- Johnson & Johnson- United States- Pharmaceuticals (2nd consecutive year featured as a top 100 Global innovator)
- Philips- Netherlands- Medical and biotechnology (2nd consecutive year featured as a top 100 Global innovator)
- Roche- Switzerland- Pharmaceuticals (11th consecutive year featured as a top 100 Global innovator)
The pharmaceuticals sector remains represented in the Top 100 Global Innovators 2022, but perhaps at a lower level than in previous years. This sector’s success in delivering vast improvement in human health, highlighted so importantly during the last 2 years, is partially due to the very high level of collaboration and partnership the sector has evolved into over the past two decades.
Read more about the full report here.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
